Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers

Inclusion Criteria:

* PRE-REGISTRATION INCLUSION
* Able to understand and willingness to sign a written informed consent document and follow study procedures
* Willing to abstain from grapefruit juice during study
* Willing to employ adequate contraception for men and women of childbearing potential; Note: acceptable methods include double barrier methods, intrauterine device (IUD), postmenopausal status documented by serum follicle stimulating hormone (FSH), and/or documentation of surgical sterilization
* Willing to provide blood and tissue specimens for research purposes
* REGISTRATION INCLUSION
* Normal organ function and have normal laboratory findings without clinically significant findings
* Leukocytes \>= 3 x 10\^3/microliter (B/L)
* Absolute neutrophil count \>= 1.5 x 10\^3/microliter (B/L)
* Platelets \>= 100 x 10\^3/microliter (B/L)
* Total bilirubin within normal institutional limits
* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/ alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 1.5 x institutional upper limit of normal (ULN)
* Creatinine =\< institutional upper limit of normal
* Body mass index \< 35 kg/m\^2
* No findings in the rectum of advanced adenoma, chronic inflammation, or cancer

Exclusion Criteria:

* PRE-REGISTRATION EXCLUSION
* Documented history of advanced adenomas (\>= 1 cm in maximal diameter, \>= 3 in total number, villous morphology, or high-grade dysplasia) or colorectal cancer
* Family history of polyposis syndrome (e.g., familial adenomatous polyposis \[FAP\], hereditary nonpolyposis colorectal cancer \[HNPCC\]) or colorectal cancer (first degree relatives younger than 60 years old)
* History of gastroparesis
* History of surgery involving the luminal gastrointestinal (GI) tract, including bariatric surgery; exception: prior appendectomy \>= 60 days prior to pre-registration is not an exclusion criterion
* History of celiac disease
* Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
* Previous diagnosis of irritable bowel syndrome, chronic constipation, functional bowel disorders, colonic motility disorder, or opioid-induced constipation
* Any malignancy within 3 years of baseline; exception: participants with a history of basal cell or squamous cell skin cancer may be enrolled at the discretion of the investigator
* Currently receiving any other investigational agents
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to dolcanatide or to any of the excipients
* History of difficulty with sigmoidoscopy or abnormal colorectal anatomy
* Uncontrolled current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Pregnant or lactating women
* Current use of laxatives more than 3 times per week
* Current use of \>= 5 cigarettes/day
* Current use of \>= 3 alcoholic drinks/day
* Use of anti-coagulants or anti-platelet agents within 5 days prior to anticipated sigmoidoscopy; exception: individuals taking aspirin will not be excluded and will not be subject to a wash-out period
* History of bleeding/coagulation problems
* Any medical condition reported by the participant or documented in the medical record that is judged by the investigator to constitute a risk to safe participation
* Known or suspected mechanical gastrointestinal obstruction
* REGISTRATION EXCLUSION
* Sigmoidoscopy finding requiring clinical intervention
* Use of any illicit or illegal substances detected by urinary drug screen